Cardinal Health, Inc. is rated a Buy with a $239 fair value, driven by specialty growth in autoimmune, urology & oncology.

Healthcare distributor and services company Cardinal Health (NYSE:CAH) will be announcing earnings results this Tuesday ...

Cardinal Health, Inc. (NYSE:CAH) will release earnings results for the fourth quarter before the opening bell on Tuesday, Aug ...

Key Insights Institutions' substantial holdings in Cardinal Health implies that they have significant influence ...

Approximately six in 10 U.S. adults reported taking a prescription drug, and a quarter of U.S. adults take four or more.

Wall Street analysts forecast that Cardinal Health (CAH) will report quarterly earnings of $2.03 per share in its upcoming release, pointing to a year-over-year increase of 10.3%. It is anticipated ...

Headquartered in Columbus, Ohio, Cardinal Health is a global, integrated healthcare services and products company that generated $205 billion in revenue in its fiscal year 2023. The company plays ...

Cardinal Health’s revenue rising 33% to $181 billion over the last twelve months, compared to $137 billion in 2017, 2. a 6% fall in its total shares outstanding to 294 million, partly offset by ...

Cardinal now expects fiscal 2024 profit in a range of $6.75 to $7.00 per share, compared with $6.50 to $6.75 it had forecast previously.

On an adjusted basis, Cardinal Health now expects to earn in the range of $5.60 to $5.80 per share in 2023, compared with its prior forecast range of $5.20 to $5.50 per share. Analysts on average ...

Cardinal Health Inc. is exploring a potential sale of its nuclear medicine business as part of a larger review of its strategy and operations, according to people familiar with the matter.

Cardinal Health is one of Ohio's largest companies by revenue, but because its drug-distribution and medical-products businesses serve mainly health-industry customers, many consumers do not know ...